Edition:
United States

PRA Health Sciences Inc (PRAH.OQ)

PRAH.OQ on NASDAQ Stock Exchange Global Select Market

82.71USD
8 Dec 2017
Change (% chg)

$1.11 (+1.36%)
Prev Close
$81.60
Open
$82.08
Day's High
$83.98
Day's Low
$81.60
Volume
157,216
Avg. Vol
222,040
52-wk High
$84.32
52-wk Low
$53.48

Summary

Name Age Since Current Position

Colin Shannon

57 2014 Chairman of the Board, President, Chief Executive Officer

Linda Baddour

58 2014 Chief Financial Officer, Executive Vice President

David Dockhorn

56 2014 Executive Vice President, Corporate Compliance Officer

Max Lin

36 2014 Director

James Momtazee

45 2014 Director

Ali Satvat

39 2014 Director

Jeffrey Barber

64 2014 Independent Director

Alexander Dickinson

2017 Independent Director

Linda Grais

61 2015 Independent Director

Matthew Young

47 2015 Independent Director

Biographies

Name Description

Colin Shannon

Mr. Colin Shannon is Chairman of the Board, President, Chief Executive Officer of PRA Health Sciences Inc. He is currently the Chairman of our Board. Colin Shannon joined PRA in 2007, serving first as President and Chief Operating Officer. Prior to joining PRA, Mr. Shannon was Executive Vice President, Global Clinical Operations at Pharmaceutical Product Development, Inc. (now known as Pharmaceutical Product Development LLC) or PPD. During his 12 year tenure with PPD, he held various leadership roles, including Chief Operating Officer for its European division and Chief Financial and Administration Officer for Europe and the Pacific Rim. Prior to joining PPD, Mr. Shannon had more than 15 years of experience in a variety of financial and accounting positions in the utility and multimedia industries. Mr. Shannon earned his M.B.A. from London's City University and is a fellow member of the Chartered Association of Certified Accountants.

Linda Baddour

Ms. Linda Baddour is Chief Financial Officer, Executive Vice President of PRA Health Sciences Inc. Ms. Linda Baddour joined PRA in 2007 as Executive Vice President and Chief Financial Officer. Before joining PRA, Ms. Baddour was Chief Financial Officer at PPD from 2002 to 2007, Chief Accounting Officer from 1997 to 2002 and Corporate Controller from 1995 to 1997. Ms. Baddour earned her M.B.A. from the University of North Carolina at Wilmington and is also a Certified Public Accountant.

David Dockhorn

Dr. David W. Dockhorn, Ph.D. is Executive Vice President, Corporate Compliance Officer of PRA Health Sciences Inc. Dr. David W. Dockhorn, Ph.D, joined PRA in 1997 as Vice President of Operations and Regional Director of our Lenexa, Kansas operations. Before joining PRA, Dr. Dockhorn worked for International Medical Technical Consultants, Inc., a CRO acquired by PRA in 1997. Mr. Dockhorn received his Ph.D in neuroscience from Texas Tech University.

Max Lin

Mr. Max C. Lin is Director of PRA Health Sciences Inc. Mr. Lin is a Director on the Health Care industry team within KKR's Private Equity platform. He also has served on the board of directors of Biomet, Inc. since 2011. Prior to joining KKR, Mr. Lin was with Morgan Stanley from 2003 to 2005 where he was involved in a number of mergers, acquisitions and financing transactions. He holds a B.S. and B.A.S. from the University of Pennsylvania and an M.B.A. from Harvard Business School.

James Momtazee

Mr. James C. Momtazee is a Director of PRA Health Sciences Inc. Mr. Momtazee is a Member of KKR and Head of the Americas Health Care industry team within KKR's Private Equity platform. He also has served on the board of directors of Lake Region Medical since 2005. He previously served on the boards of directors of Jazz Pharmaceuticals plc from 2004 to 2014 and HCA Holdings Inc. from 2006 to 2014. Prior to joining KKR, Mr. Momtazee was with Donaldson, Lufkin & Jenrette. He holds an A.B. from Stanford University and an M.B.A. from Stanford University Graduate School of Business.

Ali Satvat

Mr. Ali J. Satvat is Director of PRA Health Sciences Inc. Mr. Satvat is a Director on the Health Care industry team within KKR's Private Equity platform. He also has served on the boards of directors of Coherus BioSciences, Inc. since 2014, the Healthcare Private Equity Association since 2014 and Arbor Pharmaceuticals, Inc. since 2015. Prior to joining KKR, Mr. Satvat was a Principal with Apax Partners, where he invested in health care from 2006 to 2012, served as a director of TZ Holdings (The TriZetto Group, Inc.) from 2008 to 2012 and Chiron Holdings (Kinetic Concepts, Inc. and LifeCell Corporation) from 2011 to 2012 and was actively involved with many of the firm's successful growth investments. Previously, Mr. Satvat held various positions with Johnson & Johnson Development Corporation, Audax Group and The Blackstone Group. He holds an A.B. from Harvard College and an M.B.A. from the Wharton School of the University of Pennsylvania.

Jeffrey Barber

Mr. Jeffrey T. Barber is Independent Director of PRA Health Sciences Inc., Mr. Barber is a Managing Director with Fennebresque & Co., a Charlotte, North Carolina-based investment banking firm, where he focuses on healthcare and technology. Mr. Barber joined Fennebresque & Co. in 2009 after retiring from PricewaterhouseCoopers where he served as the Managing Partner of the Raleigh office for 14 years. Mr. Barber currently serves on the board of directors and as chair of the audit committees of Ply Gem Holdings, Inc. since January 2010 and SciQuest, Inc. since March 2010. He previously served on the board of directors and as chair of the audit committee of LipoScience, Inc. from June 2013 through November 2014. He also currently serves on the Board of Trustees of Blue Cross and Blue Shield of North Carolina since January 2009. Mr. Barber holds a B.S. in Accounting from the University of Kentucky.

Alexander Dickinson

Dr. Alexander George Dickinson serves as Independent Director of the company. Dr. Dickinson is the executive chairman of ChromaCode, a private clinical diagnostics company. Previously Dr. Dickinson was the Senior Vice President of Strategic Initiatives at Illumina, Inc. where his responsibilities included working with national governments and large institutions to develop precision medicine programs for healthcare systems. Earlier he led the team that built Illumina’s cloud-based sequencing informatics platform, BaseSpace, now one of the world’s largest genomic databases. Dr. Dickinson joined Illumina in 2010 when the company acquired Helixis, a molecular diagnostics company that he led as CEO after co-founding with Caltech Professor Axel Scherer and Nobel Laureate David Baltimore. Dr. Dickinson was previously the founder and CEO of Luxtera, a leading provider of interconnect products for cloud computing. He began his career as a researcher at AT&T Bell Labs and has been awarded over 40 patents covering a range of inventions including the camera and fingerprint CMOS chip technologies widely used in today’s smartphones. Dr. Dickinson holds a Ph.D. from the University of Adelaide, Australia, and an MBA from Columbia University in New York.

Linda Grais

Dr. Linda S. Grais, M.D. is Independent Director of PRA Health Sciences, Inc. Dr. Grais has served as a member of the board of directors of Ocera Therapeutics, Inc. since January 2008 and as president and chief executive officer of Ocera Therapeutics, Inc. since June 2012. Prior to her employment by Ocera, Dr. Grais served as a managing member at InterWest Partners, a venture capital firm from May 2005 until February 2011. From July 1998 to July 2003, Dr. Grais was a founder and executive vice president of SGX Pharmaceuticals Inc., a drug discovery company focusing on new treatments for cancer. Prior to that, she was a corporate attorney at Wilson Sonsini Goodrich & Rosati, where she practiced in such areas as venture financings, public offerings and strategic partnerships. Before practicing law, Dr. Grais worked as an assistant clinical professor of Internal Medicine and Critical Care at the University of California, San Francisco. Dr. Grais received a B.A. from Yale University, an M.D. from Yale Medical School and a J.D. from Stanford Law School. She currently serves on the board of directors of Arca Biopharma, Inc. and sits on its compensation and nominating and governance committees.

Matthew Young

Mr. Matthew P. Young is Independent Director of PRA Health Sciences, Inc. Mr. Young has served as Senior Vice President and Chief Financial Officer of Jazz Pharmaceuticals plc, since March 2014 and was promoted to Executive Vice President in February 2015. Prior to his appointment as CFO he served as Senior Vice President, Corporate Development beginning in April 2013. Prior to joining Jazz Pharmaceuticals, Mr. Young worked in investment banking for approximately 20 years. From February 2009 to April 2013, Mr. Young served as a managing director in global healthcare of Barclays Capital Inc., where his role included acting as the co-head of life sciences at Barclays Capital. From 2007 to 2008, Mr. Young served as a managing director of Citigroup Global Markets Inc., and from 2003 to 2007 he served as a managing director of Lehman Brothers Inc. From 1992 to 2003, Mr. Young served in various capacities at other investment banking firms. Mr. Young received a B.S. in Economics and an M.B.A. from the Wharton School of the University of Pennsylvania.

Basic Compensation

Name Fiscal Year Total

Colin Shannon

5,253,880

Linda Baddour

3,011,220

David Dockhorn

1,580,410

Max Lin

--

James Momtazee

--

Ali Satvat

--

Jeffrey Barber

230,318

Alexander Dickinson

--

Linda Grais

129,357

Matthew Young

195,954
As Of  30 Dec 2016

Options Compensation

Name Options Value

Colin Shannon

202,382 9,052,060

Linda Baddour

261,163 11,354,500

David Dockhorn

114,084 5,269,540

Max Lin

0 0

James Momtazee

0 0

Ali Satvat

0 0

Jeffrey Barber

0 0

Alexander Dickinson

0 0

Linda Grais

0 0

Matthew Young

0 0